Refine by
Medical Study Articles & Analysis
128 news found
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) ...
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a ...
In advance of a commercial deployment of the technology in Singapore, the parties agreed to work together to facilitate a local clinical validation study in cooperation with leading local academic medical institutions. The study will be designed to further establish the performance characteristics of the miR Sentinel™ Prostate Cancer Test ...
This was the first time the SKYLARK Study was presented at a medical congress. Zuranolone is an investigational therapy being evaluated as a once-daily, 14-day oral short course treatment in adults with major depressive disorder (MDD) and PPD. ...
Developed by specialists from the medical, technology, and design fields, the platform aims to establish a culture of preventative healthcare in Latvia as well as educate women on breast cancer risks and contraception methods. ...
RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today reveals preliminary results from an ongoing clinical study for the evaluation of the reconstruction of a 3D knee model from 2D X-ray images at Assuta Medical Center in Tel Aviv. ...
” The NUsurface Meniscus Implant is made from medical grade polymer and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. ...
Panel members included Dr Tamas Alexy, The University of Minnesota Medical School, Dr. Jeffrey Testani, Yale University Medical Center, Dr. ...
Sponsor of the trial is Linköping University with Professor Johnny Ludvigsson as the Sponsor's representative. Diamyd Medical contributes with study drug, expertise and some financial support. About Diamyd Medical Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. ...
The Sponsor of the trial has been the Norwegian University of Science and Technology with Ingrid K Hals, PhD, as Sponsor's representative. Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes. ...
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. ...
Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the DEFIANCE trial. ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...
Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic. ...
The Sponsor of the trial has been the Norwegian University of Science and Technology with Ingrid K Hals, PhD, as Sponsor's representative. Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes. ...
This increase primarily resulted from $1.4 million in costs related to the SAVVE study, $0.4 million in lab costs to support the SAVVE study and VenoValve continued development, $0.1 million increase in personnel costs due to additional staff, and $0.1 million in travel costs mainly to support the SAVVE study. About enVVeno ...
Directors of Perioperative Services, Surgeons, OR Staff and OR managers are facing high levels of stress with maintaining quality patient care, increasing surgical case volume from backlogs, while at the same time optimizing their clinical and operational efficiency, in these unprecedented times of COVID. A recent study of medical-surgical nurses found that ...
(NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that positive results of analytical and clinical studies of Bluejay’s Symphony IL-6 Test were presented at AACC 2022, the leading ...